StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a buy rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Up 0.7 %
LPCN opened at $4.15 on Friday. The stock’s 50 day moving average price is $4.67 and its 200-day moving average price is $5.34. Lipocine has a one year low of $3.30 and a one year high of $10.48.
Lipocine (NASDAQ:LPCN – Get Free Report) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.04). Equities analysts forecast that Lipocine will post -2.7 earnings per share for the current year.
Institutional Inflows and Outflows
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
- Five stocks we like better than Lipocine
- 3 Small Caps With Big Return Potential
- 2 Stocks to Get You Ready for the Holiday Season
- Why Invest in 5G? How to Invest in 5G Stocks
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- What is the Shanghai Stock Exchange Composite Index?
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.